#286
|
||||
|
||||
åùå èç ïðåæíèõ ïóáëèêàöèé, êîòîðûå ñòàëè äîñòóïíû â ñâîáîäíîé âåðñèè íåäàâíî:
IRON: HOW TO MANAGE WHEN THERE IS TOO MUCH OR TOO LITTLE OF IT DECEMBER 6, 2019 Management of iron deficiency [Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ]
__________________
Èñêðåííå, Âàäèì Âàëåðüåâè÷. |
#287
|
||||
|
||||
 ïîäòâåðæäåíèå ïðåäûäóùåé ñòàòüè ãäå ÆÄÀ àññîöèèðîâàëàñü ñ ïîâûøåíèåì ðèñêà äåìåíöèè, ýòà ïóáëèêàöèÿ ïîêàçûâàåò, ÷òî è äåôèöèò æåëåçà ïî íèçêîìó ôåððèòèíó ñíèæàåò êîãíèòèâíûå ñïîñîáíîñòè ëþäåé ñðåäíèõ ëåò è ïîæèëûõ:
SF is significantly and positively associated with cognition. In older people with low SF levels, iron supplementation may be a promising therapy to improve cognition. --- J Nutr Health Aging. 2024 Feb 17;28(4):100190. Lower serum ferritin levels are associated with worse cognitive performance in aging
__________________
Èñêðåííå, Âàäèì Âàëåðüåâè÷. |
#288
|
||||
|
||||
îöåíêà æåëåçà áèñãëèöèíàòà 25 ìã (àëÿ-Ñîëãàð) êàæäûé äåíü èëè ÷åðåç äåíü ó ñïîðòñìåíîê ñ æä ïî ôåððèòèíó ìåíåå 35 (îêîëî 20 â ñðåäíåì), åæåäíåâíûé ïðèåì ÷óòü ëó÷øå ïîâûøàë ôåððèòèí çà 8 íåäåëü (2 ìåñ. ëå÷åíèÿ), è ñòàíîâèëñÿ áîëåå 35 ó 60%, íî îí ÷àùå ñîïðîâîæäàëñÿ òîøíîòîé è çàïîðàìè; ïðèåì ÷åðåç äåíü ïåðåíîñèëñÿ ëåã÷å, íî ôåððèòèí áîëåå 35 ïîâûñèëñÿ ó 17% (ó êàæäîé øåñòîé), ïðè ôåððèòèíå ìåíåå 15 íè ó êîãî íå áûëî äîñòèãíóòî ïîâûøåíèå áîëåå 35 âíå çàâèñèìîñòè îò ðåæèìà; âîçðàñò 18-22 ãîäà, ÈÌÒ 22-23, âñå ïîäðîáíîñòè ïî ññûëêå íà îðèãèíàë:
Daily versus three times weekly dosing for treatment of iron deficiency nonanemia in NCAA Division 1 female athletes [Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ]
__________________
Èñêðåííå, Âàäèì Âàëåðüåâè÷. |
#289
|
||||
|
||||
Oral iron supplementation: new formulations, old questions. 2024
[Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ]
__________________
Èñêðåííå, Âàäèì Âàëåðüåâè÷. |
#290
|
||||
|
||||
íåêîòîðûå ìîìåíòû ïðî óñâîåíèå æåëåçà ó ÷åëîâåêà:
Iron Absorption: Molecular and Pathophysiological Aspects [Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ]
__________________
Èñêðåííå, Âàäèì Âàëåðüåâè÷. |
#291
|
||||
|
||||
ñðàâíåíèå ïàöèåíòîâ ñ Â12 äåôèöèòíîé àíåìèåé è êîìáèíèðîâàííîé â12-æåëåçîäåôèöèòíîé - ïàöèåíòû ñ êîìáè-àíåìèåé áûëè ìîëîæå (42-66 ëåò), ïðåèìóùåñòâåííî æåíùèíû, Âèòàìèí Â12 áûë 200-308 èëè íèçêîíîðìàëüíûé, ãåìîãëîáèí 121-131 èëè òîæå íèçêîíîðìàëüíûé, ãîìîöèñòåèí 11-18 èëè ïîãðàíè÷íûé; æä êàê ôåððèòèí ìåíåå 30 èëè ìåíåå 100 è Æ/ÎÆÑÑ ìåíåå 0.2, îòâåò íà ëå÷åíèå æä ïðåïàðàòàìè âíóòðü ó òðåòè ïàöèåíòîâ è ó 7/8 ïîñëå â/â ââåäåíèÿ æåëåçà:
Iron deficiency in pernicious anemia: Specific features of iron deficient patients and preliminary data on response to iron supplementation. Rogez J, Urbanski G, Vinatier E, Lavigne C, Emmanuel L, Dupin I, Ravaiau C, Lacombe V. Clin Nutr. 2024 Apr;43(4):1025-1032.
__________________
Èñêðåííå, Âàäèì Âàëåðüåâè÷. |
#292
|
||||
|
||||
áîëè ðîñòà â îáùåé ïðàêòèêå ïåäèàòðà: áûëè äèàãíîñòèðîâàíû ó 333 äåòåé â âîçðàñòå 7-8 ëåò ÷òî ñîñòàâèëî 73% îò âñåõ äåòåé ñ õðîíè÷åñêèìè áîëÿìè â íîãàõ, äëèëèñü îêîëî 11 ìåñ äî äèàãíîñòèêè; 267 äåòåé âûïîëíèëè íàçíà÷åííîå ëå÷åíèå â òå÷åíèå 3 ìåñ. è âåðíóëèñü íà ïîâòîðíûé ïðèåì; òåì, ó êîãî áûëà àíåìèÿ (ãåìîãëîáèí ìåíåå 110 ã/ë) áûë íàçíà÷åí ïðåïàðàò æåëåçà-2 ê âèòàìèíó ä è ïðåïàðàòó êàëüöèÿ, ñèìïòîìû ïðîøëè ó 67% äåòåé ïîñëå êóðñà æåëåçà è ó 29% áåç æåëåçà
72 out of 107 (67%) children, who received iron became symptom-free. Only 43 out of 160 (29%) patients became symptom-free, who received only calcium and vitamin D3 and did not receive iron. Prevalence of growing pains in a general paediatric OPD: A descriptive, observational and cross-sectional study [Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ]
__________________
Èñêðåííå, Âàäèì Âàëåðüåâè÷. |